Abnormally Increased Prolactin Levels in Women with Polycystic Ovarian Syndrome Are Associated with Risk of Obesity, Insulin Resistance and Prediabetes
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26094239 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Vesselina Yanachkova und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Specialized Hospital for Active Treatment of Obstetrics and Gynecology "Dr. Shterev", 1330 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Insulin Resistance, Prolactin, Prediabetic State. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bulgarian Ministry of Education and Science.
Abstract (Originalsprache)
Polycystic ovarian syndrome (PCOS) is a prevalent endocrine condition in women of reproductive age, characterized also by insulin resistance, affecting both obese and non-obese individuals. Hyperprolactinemia in patients with PCOS may additionally aggravate the decline in insulin sensitivity, attributable to prolactin lipogenic effects and influence on metabolic profile. Therefore, this study aimed to investigate the serum levels of prolactin in women with PCOS and their associations with obesity, insulin resistance and prediabetes. A retrospective monocentric study was performed using the electronic database of 157 women diagnosed with PCOS. Serum prolactin, BMI, complete glucose-insulin profile and insulin resistance indices following OGTT were determined. The women with hyperprolactinemia (40.8%) had significantly higher BMI (p = 0.007), fasting glucose (p = 0.003), insulin levels (p < 0.001) and HOMA-IR (p < 0.001). The women with PCOS categorized as overweight/obese (47.1%), insulin resistant (68.8%), having impaired fasting glycaemia (28.7%) and prediabetes (36.3%) showed significantly higher levels of prolactin compared to the respective counterparts. Consequently, higher prolactin levels were significantly associated with an elevated risk of development of overweight/obesity (OR 2.59; 95% CI: 1.34–4.97, p = 0.004), insulin resistance (OR 3.33; 95% CI: 1.54–7.19, p = 0.002) and prediabetes (OR 1.98; 95% CI: 1.02–3.85, p = 0.043) in women with PCOS. Our results suggest that hyperprolactinemia might be a pathophysiological link between obesity, insulin resistance, and carbohydrate metabolism impairments in patients with PCOS. Increased prolactin levels may serve as an additional indicator of insulin resistance and even further exacerbate it in women with PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Specialized Hospital for Active Treatment of Obstetrics and Gynecology "Dr. Shterev", 1330 Sofia, Bulgaria.
- Research Institute, Medical University-Pleven, 5800 Pleven, Bulgaria.
- Department of Medical Biochemistry, Faculty of Pharmacy, Medical University of Plovdiv, 4002 Plovdiv, Bulgaria.
ORCID-Profile: Teodora Stankova
Förderung
- Bulgarian Ministry of Education and Science
Zitieren
APA
Yanachkova, V., & Stankova, T. (2025). Abnormally Increased Prolactin Levels in Women with Polycystic Ovarian Syndrome Are Associated with Risk of Obesity, Insulin Resistance and Prediabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094239
Vancouver
Yanachkova V, Stankova T. Abnormally Increased Prolactin Levels in Women with Polycystic Ovarian Syndrome Are Associated with Risk of Obesity, Insulin Resistance and Prediabetes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094239
BibTeX
@article{Yanachkova2025,
author = {Yanachkova, Vesselina and Stankova, Teodora},
title = {Abnormally Increased Prolactin Levels in Women with Polycystic Ovarian Syndrome Are Associated with Risk of Obesity, Insulin Resistance and Prediabetes},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26094239}
}
EUVIMED